Filing Details

Accession Number:
0001104659-22-002722
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-10 16:07:48
Reporting Period:
2022-01-06
Accepted Time:
2022-01-10 16:07:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1802665 Harmony Biosciences Holdings Inc. HRMY Pharmaceutical Preparations (2834) 822279923
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1821102 Jeffrey Dierks 630 W. Germantown Pike, Suite 215
Plymouth Meeting, PA 19462
Chief Commercial Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-01-06 6,125 $8.22 6,125 No 4 M Direct
Common Stock Disposition 2022-01-06 1,399 $39.60 4,726 No 4 S Direct
Common Stock Disposition 2022-01-06 4,302 $40.53 424 No 4 S Direct
Common Stock Disposition 2022-01-06 424 $41.23 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option Disposition 2022-01-06 3,690 $0.00 3,690 $8.22
Common Stock Stock Option Disposition 2022-01-06 2,435 $0.00 2,435 $8.22
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
9,739 2027-10-02 No 4 M Direct
4,869 2028-10-01 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.05 to $40.04. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.07 to $41.02. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.08 to $41.39. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The stock option is currently vested with respect to 0 shares, and will vest with respect to the remainder of the shares on October 1, 2022.
  6. The stock option is currently vested with respect to 0 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on October 1, 2022.